研究单位：[1]Jiangsu HengRui Medicine Co.,Ltd.[2]Xuanwu Hospital Beijing,Capital Medical University Beijing,Beijing,China,100053
研究目的：
The study is being conducted to evaluate the safety, and the relative bioavailability of SHR0302 tablets with three different formulations in healthy subjects.
